Clinical outcome of pertussis in Sweden: association with pulsed‐field gel electrophoresis profiles and serotype
- 1 June 2007
- Vol. 115 (6) , 736-742
- https://doi.org/10.1111/j.1600-0463.2007.apm_628.x
Abstract
In Sweden, acellular pertussis vaccines were introduced at 3, 5 and 12 months of age in 1996, after a 17‐year hiatus without pertussis vaccination. An intensified surveillance of pertussis was initiated in October 1997, including collection of clinical data as well as Bordetella pertussis isolates in culture or PCR‐confirmed cases of pertussis among children born from January 1996 to September 2004. We analysed the association of pulsed‐field gel electrophoresis (PFGE) profile and serotype with severity of disease for all children followed during the first 7 years of the project. There were in all 927 children for whom both clinical information and strain characterisation data were available. 260 of these children were hospitalised during the pertussis episode. When duration of hospital stay was compared between children with different groups of strains, characterised by PFGE profile or serotype, there was a significantly higher proportion of children with long duration of hospital stay in the most frequent PFGE profile group (BpSR11) compared to the PFGE group of all other profiles (p=0.041). There was no statistically significant association between serotype and hospitalisation rate or duration of hospital stay, neither was there any statistically significant association between serotype or PFGE profile and duration of spasmodic cough or presence of complications.Keywords
This publication has 26 references indexed in Scilit:
- Long-term Follow-up of Swedish Children Vaccinated With Acellular Pertussis Vaccines at 3, 5, and 12 Months of Age Indicates the Need for a Booster Dose at 5 to 7 Years of AgePediatrics, 2006
- Shifts of Bordetella pertussis Variants in Sweden from 1970 to 2003, during Three Periods Marked by Different Vaccination ProgramsJournal of Clinical Microbiology, 2005
- Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspeciesClinical Microbiology Reviews, 2005
- Reference System for Characterization of Bordetella pertussis Pulsed-Field Gel Electrophoresis ProfilesJournal of Clinical Microbiology, 2004
- Strain Variation among Bordetella pertussis Isolates from Québec and Alberta Provinces of Canada from 1985 to 1994Journal of Clinical Microbiology, 2003
- Polymorphism of Bordetella pertussis Isolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell Vaccine Has Been Used for More than 30 YearsJournal of Clinical Microbiology, 2001
- Genotypic Variation in the Bordetella pertussis Virulence Factors Pertactin and Pertussis Toxin in Historical and Recent Clinical Isolates in the United KingdomInfection and Immunity, 2001
- Polymorphism inBordetella pertussisPertactin and Pertussis Toxin Virulence Factors in the United States, 1935–1999The Journal of Infectious Diseases, 2000
- Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccineThe Lancet, 1997
- The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United State: A Comparative studyCurrent Problems in Pediatrics, 1984